Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM).

ESMO Open · 2026 · PMC13264363 · PMID 42247790

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

22 , 32 Consistent with their known relative resistance to TKIs, patients with uncommon EGFR m and 20ins showed numerically shorter OS, although this did not reach statistical significance.

also in 111,027 other papers

showed a trendno p-value reported

Subgroup analysis of OS across different treatment regimens in patients with prior exposure to third-generation EGFR-TKIs showed a trend consistent with that of the overall population ( Supplementary Figure S4 , available at https://doi.org/10.1016/j.esmoop.2026.107743 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.